Europe's number 1 provider of laser eye surgery and a leader in spectacles, contact lenses and sunglasses.
PATIENT ADVICE: PIP breast enlargement
The MHRA* recently released a statement concerning the recent press coverage over concerns about breast enlargement procedures carried out using PIP implants stating “Our current advice to women with questions about PIP breast implants remains to seek advice from their consulting surgeon.There is no evidence of increased rupture rates associated with PIP implants.”
The Cosmetic Clinic used only a small amount of PIP implants between 2007 and 2009. We have notified all patients concerned to offer assurance and a surgeon review appointment. Following clinical advice following their appointment, if a patient chooses to have their implants removed and replaced, this will be done free of charge.
Since 2009, we have used only Eurosilicone and Allergan implants during our breast enlargement procedures.
Should you be concerned, please email Helena@thecosmeticclinic.com or call 0161 227 0036 for reassurance. Please include your name at time of surgery and your date of birth.
The Independent Healthcare Advisory Services (IHAS) has submitted evidence to the investigation into rupture rates of PIP implants collected from thousands of patients, its director Sally Taber said: "Following an audit of our members, which includes data on thousands of patients...we can confirm that the average rupture rates reported for PIP implants are within the industry standard of 1-2%."
The Medicines and Healthcare products Regulatory Agency (MHRA) is not recommending routine removal of the Poly Implant Prothese (PIP) silicone gel breast implants. There is no evidence of any disproportionate rate of implant rupture or any increase in incidence of cancer associated with these implants. The MHRA expert advisers do not believe that the risks associated with surgery from breast implant removal can be justified in the absence of further evidence.
Chief Medical Officer Dame Sally Davies said: “Women with Poly Implant Prosthese (PIP) implants should not be unduly worried. We have no evidence of a link to cancer or an increased risk of rupture. If women are concerned they should speak to their surgeon.”
As a health care organisation, we are required to follow the advice of the MHRA and the UK Department of Health.
For more information, please see http://www.mhra.gov.uk/NewsCentre/CON137888
* The Medicines and Healthcare products Regulatory Agency (MHRA) is the government agency which is responsible for ensuring that medicines and medical devices work, and are acceptably safe. The MHRA is an executive agency of the Department of Health.
